Skip to main content

Table 3 Results of univariable logistic regression predicting likelihood of ≥ 50% response in MHD

From: Impact of a reimbursement policy change on treatment with erenumab in migraine – a real-world experience from Germany

 

Coefficient (β)

S.E

Wald

df

P

Odds Ratio

95% CI for Odds Ratio

Lower

Upper

New policy

1.06

0.31

11.44

1

0.01

2.88

1.56

5.30

Sex (female)

-0.43

0.37

1.31

1

0.25

0.65

0.32

1.35

Age (yrs)

-0.01

0.11

0.43

1

0.51

0.99

0.97

1.02

Disease duration (yrs)

-0.01

0.11

0.95

1

0.33

0.99

0.97

1.01

MHD at baseline

-0.52

0.02

5.87

1

0.02

0.95

0.91

0.99

Daily headaches

-0.58

0.43

1.80

1

0.18

0.56

0.24

1.31

Start with 140 mg

0.71

0.35

4.11

1

0.04

2.04

1.02

4.06

Comorbid depression

-0.60

0.31

3.81

1

0.05

0.55

0.30

1.00

Chronic migraine

-0.64

0.28

5.20

1

0.23

0.53

0.30

0.91

  1. Abbreviations: MHD monthly headache days S.E. standard error CI confidence interval